Ho YY - Search Results

1

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

Lefèvre G, Pommier F, Sedek G, Allison M, Huang HL, Kiese B, Ho YY, Appel-Dingemanse S. Lefèvre G, et al. Among authors: ho yy. J Clin Pharmacol. 2008 Feb;48(2):246-52. doi: 10.1177/0091270007312154. J Clin Pharmacol. 2008. PMID: 18199897 Clinical Trial. No abstract available.

2

Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.

Lu Y, Yang S, Ho YY, Ji Y. Lu Y, et al. Among authors: ho yy. J Clin Pharmacol. 2021 Aug;61(8):1054-1068. doi: 10.1002/jcph.1856. Epub 2021 Apr 17. J Clin Pharmacol. 2021. PMID: 33713359 Clinical Trial.

3

Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.

Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Combes FP, et al. Among authors: ho yy. Clin Pharmacol Ther. 2022 Nov;112(5):1040-1050. doi: 10.1002/cpt.2699. Epub 2022 Jul 31. Clin Pharmacol Ther. 2022. PMID: 35776072 Clinical Trial.

4

Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.

Ji Y, Darstein C, Yang S, Quinlan M, Chakravartty A, Zarate JP, Chakraborty A, Ho YY. Ji Y, et al. Among authors: ho yy. J Clin Pharmacol. 2023 Dec;63(12):1359-1370. doi: 10.1002/jcph.2310. Epub 2023 Aug 1. J Clin Pharmacol. 2023. PMID: 37464901

5

Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients.

Lau YY, Gu W, Ho YY, Hong Y, Zhang X, Urban P. Lau YY, et al. Among authors: ho yy. Cancer Chemother Pharmacol. 2019 Sep;84(3):501-511. doi: 10.1007/s00280-019-03830-5. Epub 2019 Apr 24. Cancer Chemother Pharmacol. 2019. PMID: 31020351 Clinical Trial.

6

Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.

Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Li YF, et al. Among authors: ho yy. Clin Pharmacokinet. 2022 Oct;61(10):1475-1476. doi: 10.1007/s40262-022-01166-7. Clin Pharmacokinet. 2022. PMID: 35976571 No abstract available.

7

Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.

Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Li YF, et al. Among authors: ho yy. Clin Pharmacokinet. 2022 Oct;61(10):1393-1403. doi: 10.1007/s40262-022-01148-9. Epub 2022 Jun 28. Clin Pharmacokinet. 2022. PMID: 35764773 Clinical Trial.

8

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.

Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, Hoch M, Ho YY. Combes FP, et al. Among authors: ho yy. Clin Pharmacokinet. 2024 Sep;63(9):1301-1312. doi: 10.1007/s40262-024-01411-1. Epub 2024 Sep 7. Clin Pharmacokinet. 2024. PMID: 39243304 Free PMC article. Clinical Trial.

9

Chemical Auxiliary for Photocatalytic Active Colloids.

Duan W, Mu Y, Mo X, Wang Z, Zhang T, Ho YYL, Lyu D, Zhang D, Zhao R, Tse ECM, Gao Y, Wu H, Wang Y. Duan W, et al. Among authors: ho yyl. J Am Chem Soc. 2024 Sep 25;146(38):26505-26515. doi: 10.1021/jacs.4c10100. Epub 2024 Sep 10. J Am Chem Soc. 2024. PMID: 39254864

10

2024 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong.

OSHK Task Group for the Formulation of the 2024 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong; Ip TP, Lee CA, Lui TD, Wong RMY, Cheung CL, Chiu KCP, Chow SLE, Ho CF, Ho TC, Ho YA, Lee KK, Li HR, Mak KC, Ng KD, Ngai SLI, Wong CG, Wong SJ, Wong SH, Wong TW. OSHK Task Group for the Formulation of the 2024 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, et al. Hong Kong Med J. 2024 Apr;30 Suppl 2:1-44. Hong Kong Med J. 2024. PMID: 39113555 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters